Nykode Therapeutics Denmark A/S: Financial statements 2022
CVR: 42038660
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 38,639,042 and a net result of DKK 1,895,426 compared with DKK 578,082 the year before. That is an increase of 264.8% compared with the year before. Equity in the 2022 report amounted to DKK 2,873,508. The solvency ratio was 19.4%. The company had 23 employees in the financial year.
- Gross Profit
- DKK 38,639,042
- Profit/Loss
- DKK 1,895,426
- Equity
- DKK 2,873,508
- Total Assets
- DKK 14,830,214
- Employees
- 23
Official annual report
Keep an eye on Nykode Therapeutics Denmark A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of August 15, 2022, Louise Stubbe has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Harald Gurvin has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Katrine Hovgaard Husum has left the board of directors of Nykode Therapeutics Denmark A/S.
As of August 15, 2022, Alf Gunnar Martin Nicklasson has left the board of directors of Nykode Therapeutics Denmark A/S.
Nykode Therapeutics Denmark A/S has published its annual report for 2021. Gross profit came to DKK 10,590,585, and the net result was DKK 578,082.
As of January 20, 2022, Alf Gunnar Martin Nicklasson has joined the board of directors of Nykode Therapeutics Denmark A/S.
As of January 20, 2022, Anders Tuv has left the board of directors of Nykode Therapeutics Denmark A/S.
About Nykode Therapeutics Denmark A/S
Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.
